Page last updated: 2024-08-26

paxilline and s 1033

paxilline has been researched along with s 1033 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barrett, A; Brandner, S; Evans, IM; Frankel, P; Frolov, A; Li, N; Lockwood, N; Paliashvili, K; Sidlauskas, K; Zachary, IC1

Other Studies

1 other study(ies) available for paxilline and s 1033

ArticleYear
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
    Scientific reports, 2016, 06-13, Volume: 6

    Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Discoidin Domain Receptor 1; Focal Adhesion Kinase 1; Glioblastoma; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction

2016